BioMed X Starts New Project with Janssen

Pharma Tech Outlook: Pharma Tech Magazine

BioMed X Starts New Project with Janssen

By Pharma Tech Outlook | Tuesday, February 16, 2021

BioMed X announces its latest research project with Janssen Research & Development, one of Johnson & Johnson's Janssen Pharmaceutical Firms.

FREMONT, CA: BioMed X, an independent German research institute, announces its latest research project with Janssen Research & Development, LLC, one of Johnson & Johnson's Janssen Pharmaceutical Firms. It will aim to explore novel transport pathways in the human intestinal tract that could be used for oral delivery of different therapeutic methods. Biologics like monoclonal antibodies have transformed the treatment of immune-related diseases, but it needs to be administered by injection, which could have more significant obstacles to use compared to oral delivery. Johnson & Johnson Creativity initiated the partnership.

Christian Tidona, Founder and Managing Director of the BioMed X Institute, said "There are several techniques available to shield these macromolecules from the harsh conditions of the gastrointestinal tract, but little progress has been made to translocate complex macromolecules across the intestinal epithelial barrier into systemic circulation. This project has the potential to provide us with a novel delivery platform that enables the development of a new generation of oral immunotherapies."

The current call for applications targets Early-career biomedical researchers with an excellent background or keen interest in the field of drug delivery. The BioMed X Institute plans to employ one group leader, two postdoctoral researchers, and two research assistants for this fully funded research project. Interested applicants are required to present a competitive project plan as part of the online application process. The candidates will be invited to a five-day innovation boot camp in Heidelberg after the first selection round. The boot camp will take place online if pandemic regulations do not permit onsite meetings.

BioMed X is an autonomous research institute based in Germany on the campus of the University of Heidelberg. They recognize major biomedical research issues together with their collaborators and provide groundbreaking solutions by integrating global crowdsourcing with local incubation of the world's brightest early-career research talents. At BioMed X, each one of the highly diverse research teams has access to state-of-the-art research facilities and are actively directed by established academic and industry mentors.

Weekly Brief


Read Also